Rheumatoid Arthritis trial readouts
registry pull 2026-08-19Primary-completion dates that listed drug and biotech companies filed with ClinicalTrials.gov for studies in Rheumatoid Arthritis. They are the sponsor's own estimated windows, revised as a study runs — not announcement dates. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Upcoming readout windows
next 180 days · by month7 studies across 3 companies, in the next 180 days.
October 2026 1
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| SYRE | Spyre Therapeutics, Inc. | A Study of SPY072 in Rheumatic DiseaseNCT07148414Rheumatoid Arthritis: Change from baseline in Disease Activity Score in 28 joints (c-reactive protein) (DAS-CRP) | Phase 2 | Active, not recruiting | 2026-10-31 | in 72 d | 2026-06-05 |
December 2026 4
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| ZBH | Zimmer Biomet | Outcomes Study of the Trabecular Metal (TM) Reverse Shoulder SystemNCT01480440observationalSurvivorship | — | Active, not recruiting | Dec 2026 | ≤ 133 d | 2026-04-28 |
| ZBH | Zimmer Biomet | Comprehensive Reverse Shoulder Data CollectionNCT03404778observationalPain Score | — | Enrolling by invitation | Dec 2026 | ≤ 133 d | 2025-10-30 |
| ZBH | Zimmer Biomet | Database Retrieval for the Comprehensive ShoulderNCT03409718observationalImplant survivorship is assessed counting the number of implant revisions | — | Active, not recruiting | Dec 2026 | ≤ 133 d | 2026-07-10 |
| ZBH | Zimmer Biomet | Post Market Clinical Follow-up (PMCF) Study of the A.L.P.S. Proximal Humerus Plating SystemNCT03626038Re-operation | Not applicable | Active, not recruiting | Dec 2026 | ≤ 133 d | 2026-02-13 |
January 2027 2
| Ticker | Name | Study | Phase | Status | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|
| XBIT | XBiotech, Inc. | Natrunix in Combination With Methotrexate for Rheumatoid Arthritis TreatmentNCT06590090ACR 20 response | Phase 2 | Not yet recruiting | 2027-01-15 | in 148 d | 2025-12-09 |
| ZBH | Zimmer Biomet | ROSA Knee Intraoperative Planning Flexibility StudyNCT05966519observationalThe mean absolute difference between X-Atlas image based pre-op plan & intra-op final plan | — | Recruiting | Jan 2027 | ≤ 164 d | 2026-04-08 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Every registered study in Rheumatoid Arthritis
most recently updated first653 studies match. Showing the first 100 of 653 studies — page through, or narrow the filters.
| Ticker | Name | Market cap | Study | Phase | Status | Interventions | Conditions | Enrollment | Start | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ZBH | Zimmer Biomet | $18.9B | Persona Ti-Nidium Post-Market Clinical Follow-upNCT04817969Oxford Knee Score (OKS) | Not applicable | Active, not recruiting | Device: Zimmer Biomet Persona Ti-Nidium Total Knee System | Knee Pain Chronic, Osteoarthritis, Rheumatoid Arthritis, Traumatic Arthritis, Polyarthritis, Varus Deformity, Valgus Deformity, Flexion Deformity of the Knee, Avascular Necrosis, Patellofemoral Osteoarthritis | 240 | 2021-06-01 | May 2034 | ≤ 2,841 d | 2026-08-17 |
| ABBV | AbbVie | $457.5B | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid ArthritisNCT05814627Percentage of Participants Achieving Disease Activity Score 28 C-reactive Protein [DAS28-CRP]) <= 3.2 | Phase 3 | Completed | Drug: Upadacitinib, Adalimumab, Upadacitinib Matching Placebo, Adalimumab Matching Placebo | Rheumatoid Arthritis | 487 | 2023-06-15 | 2026-07-15actual | — | 2026-08-14 |
| SNN | Smith & Nephew, Inc. | — | A Global Clinical Study Investigating the Safety and Effectiveness of Smith and Nephew's Porous Knee System in Patients Who Need a Total Knee Replacement Due to Degenerative Arthritis, Post-traumatic Arthritis or Inflammatory ArthritisNCT05197036observationalImplant Survivorship (femoral and/or tibial component) 2 Years Post-Surgery | — | Active, not recruiting | Procedure: Total Knee Arthroplasty | Osteoarthritis, Post-traumatic Arthritis, Rheumatoid Arthritis | 299 | 2021-12-21 | 2026-06-11actual | — | 2026-08-11 |
| PHIL.MI | Philogen S.p.A. | $1.1B | A Study of F8IL10 Intra-articular Treatment in Rheumatoid ArthritisNCT07245992DLT | Phase 1 | Recruiting | Drug: F8IL10 | Rheumatoid Arthritis (RA) | 42 | 2026-03-04 | 2028-09-30 | in 772 d | 2026-08-11 |
| SNY | Sanofi | — | Phase 1b/2 Study of IV Sarilumab in Adult With RANCT07704580Part A: Assessment of Pharmacokinetic (PK) parameters of sarilumab in serum: area under the concentration-time curve [AUClast] for IV doses | Phase 1/2 | Recruiting | Drug: Sarilumab, SAR153191 SC, Sarilumab, SAR153191 IV | Rheumatoid Arthritis | 140 | 2026-07-02 | 2028-10-26 | in 798 d | 2026-08-11 |
| NKTX | Nkarta, Inc. | $173M | A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)NCT06733935Incidence of Dose-limiting toxicities (DLTs) [Safety and Tolerability] | Phase 1/2 | Recruiting | Drug: NKX019, Fludarabine, Cyclophosphamide | Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Antineutrophil Cytoplasmic Antibody-Associated Vasculitis, Rheumatoid Arthritis | 240 | 2024-11-04 | Oct 2028 | ≤ 803 d | 2026-08-07 |
| XNCR | Xencor, Inc. | $1.9B | A Phase 1b Open-label Study to Evaluate Safety of Plamotamab in Participants With Rheumatoid ArthritisNCT07230353Primary | Phase 1 | Recruiting | Biological: Plamotamab | Rheumatoid Arthritis | 68 | 2025-10-21 | Jun 2028 | ≤ 680 d | 2026-08-03 |
| ARTV | Artiva Biotherapeutics, Inc. | $571M | AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.NCT06991114Safety | Phase 2 | Recruiting | Drug: Allogeneic NK Cells | Refractory Rheumatoid Arthritis (RA), Idiopathic Inflammatory Myopathies (IIMs), Systemic Sclerosis (SSc), Rheumatoid Arthritis (RA, IIM, Myositis, Scleroderma, Sjogren Syndrome, Sjogrens Disease | 90 | 2025-07-09 | Jan 2028 | ≤ 529 d | 2026-07-31 |
| ABBV | AbbVie | $457.5B | A Comparison Study of Persistence of UPadacitinib vs. TNF-inhibitoRs In a German Real-world SettINGNCT06712628observationalRetention Rate of UPA vs TNFi | — | Recruiting | — | Moderate to Severe Rheumatoid Arthritis | 678 | 2024-11-07 | Dec 2028 | ≤ 864 d | 2026-07-30 |
| AZN | AstraZeneca | — | Study Evaluating Safety, Tolerability, PK/PD of Surovatamig in Adult RA or SLE ParticipantsNCT07201558Safety evaluation of surovatamig: Number of participants with treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), adverse events of special interest (AESIs) | Phase 1 | Recruiting | Biological: Surovatamig | Rheumatoid Arthritis, Systemic Lupus Erythematosus | 48 | 2025-12-02 | 2028-06-27 | in 677 d | 2026-07-29 |
| AZN | AstraZeneca | — | A Study of AZD0120 in Autoimmune DiseasesNCT07295847Number of participants and severity of dose limiting toxicities (DLTs) and treatment-emergent adverse events (TEAEs) | Phase 1 | Recruiting | Biological: AZD0120 | Systemic Sclerosis, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis | 27 | 2026-01-09 | 2028-02-22 | in 551 d | 2026-07-28 |
| AZN | AstraZeneca | — | A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD5492 in Adult Participants With Systemic Lupus Erythematosus or Idiopathic Inflammatory Myopathies or Rheumatoid Arthritis.NCT06916806Safety evaluation of AZD5492: Number of participants with treatment-emergent adverse events. | Phase 1 | Recruiting | Drug: AZD5492 | Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathies, Rheumatoid Arthritis | 72 | 2025-05-01 | 2027-05-05 | in 258 d | 2026-07-23 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986454 in Participants With Rheumatoid ArthritisNCT07171983Number of participants with adverse events (AEs) | Phase 1 | Recruiting | Drug: BMS-986454 · Other: Placebo | Rheumatoid Arthritis | 46 | 2026-02-27 | 2027-06-28 | in 312 d | 2026-07-20 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY4298445 in Healthy Participants and Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)NCT07276958Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration | Phase 1 | Recruiting | Drug: LY4298445, LY4298445 | Healthy, Systemic Lupus Erythematosus, Rheumatoid Arthritis | 63 | 2026-02-04 | Mar 2028 | ≤ 589 d | 2026-07-17 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study of BMS-986528 in Participants With Refractory Rheumatoid ArthritisNCT07412704Number of participants with treatment-emergent adverse events (TEAEs) | Phase 1/2 | Not yet recruiting | Drug: BMS-986528 | Arthritis, Rheumatoid | 84 | 2026-09-15 | 2029-10-30 | in 1,167 d | 2026-07-17 |
| ZBH | Zimmer Biomet | $18.9B | G7 Acetabular System With Vivacit-E or Longevity Liner PMCF StudyNCT04754087Survival of the study device (liner); whether or not it is still implanted in the subject | Not applicable | Active, not recruiting | Device: Vivacit-E and Longevity (HXLPE) Liners | Total Hip Arthroplasty, Degenerative Joint Disease of Hip, Avascular Necrosis of Hip, Rheumatoid Arthritis of Hip, Osteoarthritis, Hip, Osteoarthritis of Hip, Fractures, Hip, Fracture of Hip | 300 | 2021-07-07 | 2033-12-31 | in 2,690 d | 2026-07-16 |
| ZBH | Zimmer Biomet | $18.9B | Database Retrieval for the Comprehensive ShoulderNCT03409718observationalImplant survivorship is assessed counting the number of implant revisions | — | Active, not recruiting | Device: Biomet Comprehensive Shoulder System | Osteoarthritis of the Shoulder, Avascular Necrosis, Rheumatoid Arthritis, Prior Failed Revision, Correction of Functional Deformity, Fracture of Proximal End of Humerus, Cuff Tear Arthropathy | 160 | 2011-02-24 | Dec 2026 | ≤ 133 d | 2026-07-10 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Baricitinib in Participants With Rheumatoid ArthritisNCT04086745results2026-07-10Pooled JAJA and JAJD: Time From First Dose of Study Treatment to First Event of Venous Thromboembolism (VTE) [Combined Baricitinib Dose Versus TNF Inhibitor] | Phase 4 | Completed | Drug: Baricitinib, TNF Inhibitor | Rheumatoid Arthritis | 1,050 | 2020-02-14 | 2025-05-19actual | — | 2026-07-10 |
| ZBH | Zimmer Biomet | $18.9B | Persona OsseoTi Keel Compatibility Study (Total Knee Arthroplasty)NCT05787821observationalOxford Knee Score (OKS) | — | Active, not recruiting | Device: Total Knee Arthroplasty | Knee Pain Chronic, Osteoarthritis, Knee, Rheumatoid Arthritis, Traumatic Arthritis, Polyarthritis, Varus Deformity, Valgus Deformity, Flexion Deformity of Knee, Avascular Necrosis | 760 | 2023-06-28 | 2026-06-30actual | — | 2026-07-10 |
| ABBV | AbbVie | $457.5B | A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid ArthritisNCT06972446Percentage of Participants With an American College of Rheumatology 50% (ACR50) Response | Phase 2 | Recruiting | Drug: Lutikizumab, Placebo, Ravagalimab | Rheumatoid Arthritis | 180 | 2025-06-20 | Feb 2027 | ≤ 192 d | 2026-07-10 |
| ZBH | Zimmer Biomet | $18.9B | Zimmer Trabecular Metal Total Ankle PMCFNCT02038140Survivorship | Not applicable | Active, not recruiting | Device: Zimmer Trabecular Metal Total Ankle System | Degenerative Arthritis, Rheumatoid Arthritis, Post Traumatic Arthritis | 120 | Mar 2014 | Sep 2027 | ≤ 406 d | 2026-07-09 |
| ZBH | Zimmer Biomet | $18.9B | Post-Market Study of Comprehensive Reverse Augmented Glenoid and Mini Humeral Tray in Total Shoulder ArthroplastyNCT03726554Implant Survivorship | Not applicable | Active, not recruiting | Device: Comprehensive Reverse Porous Augmented Glenoid, Comprehensive Mini Humeral Tray | Arthropathy of Shoulder Region, Grossly Deficient Rotator Cuff, Osteoarthritis of the Shoulder, Rheumatoid Arthritis Without Humeral Metaphyseal Defects, Post-Traumatic Arthritis | 99 | 2018-08-28 | Feb 2030 | ≤ 1,288 d | 2026-07-09 |
| ABBV | AbbVie | $457.5B | A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions and Subcutaneous Injections of ABBV-519 in Adult Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)NCT07607964Change from Baseline in B Cells in Blood | Phase 1 | Recruiting | Drug: ABBV-519, ABBV-519 | Systemic Lupus Erythematosus, Rheumatoid Arthritis | 30 | 2026-05-28 | Jan 2029 | ≤ 895 d | 2026-07-01 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Baricitinib (LY3009104) in Participants With Rheumatoid ArthritisNCT03915964results2026-06-24Pooled JAJA and JAJD: Time From First Dose of Study Treatment to First Event of Venous Thromboembolism (VTE) [Combined Baricitinib Dose Versus TNF Inhibitor] | Phase 4 | Completed | Drug: Baricitinib, TNF Inhibitor | Rheumatoid Arthritis | 2,659 | 2019-04-25 | 2025-05-28actual | — | 2026-06-24 |
| AZN | AstraZeneca | — | A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid ArthritisNCT07276581Change From Baseline in Disease Activity Score-C-Reactive Protein (DAS28-CRP) at Week 12 | Phase 2 | Recruiting | Drug: AZD1163 · Other: Placebo | Rheumatoid Arthritis | 320 | 2025-12-15 | 2027-11-12 | in 449 d | 2026-06-24 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY4213663 in Healthy Participants and Participants With Rheumatoid ArthritisNCT07258849Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration | Phase 1 | Recruiting | Drug: LY4213663, LY4213663, Placebo, Placebo | Rheumatoid Arthritis (RA) | 141 | 2025-12-02 | Mar 2028 | ≤ 589 d | 2026-06-23 |
| SNN | Smith & Nephew, Inc. | — | Long Term Follow-up of Integra® Cadence™ Total Ankle System in Primary Ankle Joint ReplacementNCT03247023results2026-06-22observationalImplant Survivorship at 2 Years | — | Terminatedsponsor's stated reason: Sponsor decision not related to safety | Device: Implantation of Integra Cadence Total Ankle System | Degenerative Arthritis, Rheumatoid Arthritis, Traumatic Arthritis | 65 | 2017-09-18 | 2023-09-06actual | — | 2026-06-22 |
| LLY | Eli Lilly and Company | $1.15T | A Study of LY3541860 in Adult Participants With Moderately to Severely Active Rheumatoid ArthritisNCT06859294Change from Baseline in Disease Activity Score - High-Sensitivity C-Reactive Protein (DAS28 - hsCRP) | Phase 2 | Terminatedsponsor's stated reason: The interim analysis data failed to demonstrate the intended treatment effect. | Drug: LY3541860 | Rheumatoid Arthritis | 35 | 2025-03-19 | 2025-11-10actual | — | 2026-06-17 |
| SNY | Sanofi | — | A Study of the Effectiveness of Additional Risk Minimization Measures Related to ARAVA® (Leflunomide) in Saudi ArabiaNCT06714461observationalNumber of healthcare professionals who recall receiving and reading the additional risk minimization measures material for leflunomide distributed in 2022 | — | Completed | Drug: Leflunomide | Rheumatoid Arthritis, Psoriatic Arthritis | 302 | 2025-05-05 | 2026-05-14actual | — | 2026-06-11 |
| 4503.T | Astellas Pharma Inc | $26.0B | Japan Post-Marketing Surveillance for Peficitinib to Assess Safety and Effectiveness in the Patients With Rheumatoid ArthritisNCT03971253observationalSafety assessed by frequency of adverse events (AEs) | — | Completed | Drug: Peficitinib | Rheumatoid Arthritis (RA) | 3,000 | 2019-09-02 | 2026-05-29actual | — | 2026-06-10 |
| ZBH | Zimmer Biomet | $18.9B | Comprehensive Segmental Revision SystemNCT03270982observationalImplant survivorship assessed according to the implant revisions | — | Active, not recruiting | Device: Comprehensive SRS Replacement | Degenerative Disease, Oncology, Revision Surgery, Trauma, Rheumatoid Arthritis | 105 | Apr 2016 | Dec 2035 | ≤ 3,420 d | 2026-06-09 |
| ZBH | Zimmer Biomet | $18.9B | TESS V3 Modular Total Shoulder System PMCFNCT05002959observationalImplant survival at 10 years | — | Terminatedsponsor's stated reason: Termination of PMCF study due to product discontinuation (commercial reasons) | Device: Anatomic TESS V3, Reverse TESS V3 | Osteoarthritis Shoulder, Rheumatoid Arthritis, Rheumatoid Arthritis Shoulder, Avascular Necrosis, Revision, Rotator Cuff Tears, Osteonecrosis, Rotator Cuff Tear Arthropathy, Proximal Humeral Fracture, Malunion of Fracture, Shoulder Region | 67 | 2022-02-01 | 2026-03-05actual | — | 2026-06-09 |
| GILD | Gilead Sciences | $177.9B | Study of GS-0151 in Participants With Rheumatoid ArthritisNCT06902519Cohort 1, 2 and 3: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) | Phase 1 | Recruiting | Drug: GS-0151, Placebo | Rheumatoid Arthritis | 75 | 2025-05-14 | Mar 2027 | ≤ 223 d | 2026-06-09 |
| ZBH | Zimmer Biomet | $18.9B | Sidus(TM) Post Market Clinical Follow-up (PMCF) StudyNCT01700543observationalFunctional Performance (Constant & Murley Score) | — | Completed | Procedure: Shoulder Arthroplasty | Non-inflammatory Degenerative Joint Disease (NIDJD), Avascular Necrosis, Osteoarthritis, Inflammatory Joint Disease (IJD), Rheumatoid Arthritis | 152 | Oct 2012 | Jul 2020actual | — | 2026-06-08 |
| SYRE | Spyre Therapeutics, Inc. | $9.5B | A Study of SPY072 in Rheumatic DiseaseNCT07148414Rheumatoid Arthritis: Change from baseline in Disease Activity Score in 28 joints (c-reactive protein) (DAS-CRP) | Phase 2 | Active, not recruiting | Drug: SPY002-072, Placebo | Rheumatoid Arthritis, Psoriatic Arthritis, Axial Spondyloarthritis, Rheumatic Diseases, Rheumatic Joint Disease, PsA (Psoriatic Arthritis), AxSpA, Rheumatologic Disease | 285 | 2025-08-21 | 2026-10-31 | in 72 d | 2026-06-05 |
| ABBV | AbbVie | $457.5B | Study To Assess Frequency Of Serious Infections In Clinical Practice In Japan For Adult Participants With Rheumatoid Arthritis Receiving Oral RINVOQ TabletsNCT04340115observationalNumber (Percentage) Of Participants Who Reported Of Serious Infection | — | Completed | — | Rheumatoid Arthritis (RA) | 4,211 | 2020-04-24 | 2025-08-15actual | — | 2026-06-03 |
| GILD | Gilead Sciences | $177.9B | Study of GS-0272 in Participants With Rheumatoid ArthritisNCT06031415Percentage of Participants Experiencing Adverse Events (AEs) | Phase 1 | Terminatedsponsor's stated reason: Study terminated due to lack of efficacy. | Drug: GS-0272, Placebo | Rheumatoid Arthritis | 55 | 2023-09-28 | 2026-05-11actual | — | 2026-05-27 |
| LLY | Eli Lilly and Company | $1.15T | An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid ArthritisNCT05848258Phase 2a: Change from Baseline in Disease Activity Score - high-sensitivity C-reactive protein (DAS28-hsCRP) | Phase 2 | Completed | Drug: LY3871801, Placebo | Rheumatoid Arthritis | 164 | 2023-05-23 | 2025-12-08actual | — | 2026-05-22 |
| SNY | Sanofi | — | A Study to Evaluate the Safety and Activity of SAR448501/DR-0201 in Patients With Autoimmune Rheumatic DiseasesNCT06647069Incidence of treatment-emergent adverse events (TEAEs) | Phase 1 | Recruiting | Drug: SAR448501 | Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA) | 62 | 2025-03-27 | 2029-06-25 | in 1,040 d | 2026-05-22 |
| CGEM | Cullinan Therapeutics Inc. | $1.3B | A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Rheumatoid ArthritisNCT06994143Incidence and severity of adverse events | Phase 1 | Recruiting | Drug: CLN-978 | Rheumatoid Arthritis (RA | 37 | 2025-05-19 | 2027-12-30 | in 497 d | 2026-05-15 |
| ZBH | Zimmer Biomet | $18.9B | ROSA Total Knee Post Market Study EMEANCT04338893results2026-01-21Alignment Accuracy | Not applicable | Completed | Procedure: Device: Persona Total Knee, Device: NexGen Total Knee, Device: Vanguard Total Knee | Knee Pain, Chronic Osteoarthritis, Avascular Necrosis of the Femoral Condyle, Moderate Varus, Valgus or Flexion Deformities, Rheumatoid Arthritis | 252 | 2020-12-15 | 2025-08-22actual | — | 2026-05-12 |
| ZBH | Zimmer Biomet | $18.9B | Outcomes Study of the Trabecular Metal (TM) Reverse Shoulder SystemNCT01480440observationalSurvivorship | — | Active, not recruiting | Device: Trabecular Metal Reverse Shoulder System | Osteoarthritis, Rheumatoid Arthritis, Post-traumatic Arthritis, Ununited Humeral Head Fracture, Irreducible 3-and 4-part Proximal Humeral Fractures, Avascular Necrosis, Gross Rotator Cuff Deficiency, Revision Total Shoulder Arthroplasty | 200 | Jan 2011 | Dec 2026 | ≤ 133 d | 2026-04-28 |
| ZBH | Zimmer Biomet | $18.9B | Cemented vs Cementless Persona Keel RCTNCT05630053Oxford Knee Score (OKS) | Not applicable | Active, not recruiting | Device: Cementless Persona Knee System, Cemented Persona Knee System | Knee Pain Chronic, Rheumatoid Arthritis, Osteoarthritis, Traumatic Arthritis, Polyarthritis, Avascular Necrosis, Varus Deformity, Valgus Deformity, Flexion Deformity of Knee | 300 | 2023-07-25 | May 2032 | ≤ 2,111 d | 2026-04-27 |
| ZBH | Zimmer Biomet | $18.9B | Comprehensive Nano - Post Market Clinical Follow-Up StudyNCT03423953observationalSurvivorship | — | Active, not recruiting | Device: Comprehensive Nano | Osteoarthritis, Avascular Necrosis, Rheumatoid Arthritis, Revision, Correction of Functional Deformity | 194 | 2013-10-30 | 2030-07-31 | in 1,441 d | 2026-04-21 |
| ZBH | Zimmer Biomet | $18.9B | ROSA Knee Intraoperative Planning Flexibility StudyNCT05966519observationalThe mean absolute difference between X-Atlas image based pre-op plan & intra-op final plan | — | Recruiting | Device: Total Knee Replacement (TKR) | Osteo Arthritis Knee, Rheumatoid Arthritis | 80 | 2024-01-05 | Jan 2027 | ≤ 164 d | 2026-04-08 |
| 068270.KS | Celltrion | $30.7B | A Study to Evaluate the Safety of Remsima® SC in the Treatment of RA, AS, PsA and PsNCT05866614observationalevaluation of adverse events of special interest (AESI) | — | Active, not recruiting | Drug: Remsima IV, Remsima SC | Rheumatoid Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Psoriasis | 881 | 2023-01-13 | Mar 2027 | ≤ 223 d | 2026-03-31 |
| IXHL | Incannex Healthcare Ltd | $116M | Safety and Effect on Pain and Function According to RAPID-3 of IHL-675A in Patients With Rheumatoid ArthritisNCT05942911Change in pain and function | Phase 2 | Terminatedsponsor's stated reason: Recruitment challenges | Drug: IHL-675A, Cannabidiol, Hydroxychloroquine, Placebo | Rheumatoid Arthritis | 20 | 2023-11-22 | 2024-10-28actual | — | 2026-03-27 |
| ZBH | Zimmer Biomet | $18.9B | Anatomical Shoulder Domelock System StudyNCT03312465observationalImplant Survivorship | — | Active, not recruiting | Device: AS Domelock System | Avascular Necrosis, Revision Surgery, Conditions Consequent to Earlier Operations, Arthritis, Rheumatoid, Arthritis, Degenerative, Arthritis;Traumatic | 73 | 2017-09-28 | 2032-12-09 | in 2,303 d | 2026-03-25 |
| ZBH | Zimmer Biomet | $18.9B | Persona Total Knee Arthroplasty Outcomes StudyNCT02255383Knee Society Score | Not applicable | Active, not recruiting | Device: Zimmer Persona Total Knee System | Knee Pain Chronic, Osteoarthritis, Rheumatoid Arthritis, Traumatic Arthritis, Polyarthritis, Moderate Varus, Valgus or Flexion Deformities, Avascular Necrosis of the Femoral Condyle | 737 | Jul 2014 | Dec 2025actual | — | 2026-03-10 |
| ZBH | Zimmer Biomet | $18.9B | Post Market Clinical Follow-up (PMCF) Study of the A.L.P.S. Proximal Humerus Plating SystemNCT03626038Re-operation | Not applicable | Active, not recruiting | Device: A.L.P.S. Proximal Humerus Plating System | Osteoarthritis, Rheumatoid Arthritis, Post-Traumatic Arthritis, Psoriatic Arthritis, Proximal Humeral Fracture | 135 | 2018-06-19 | Dec 2026 | ≤ 133 d | 2026-02-13 |
| ABBV | AbbVie | $457.5B | A Study of Oral Upadacitinib (RINVOQ) Tablets to Assess Adverse Events and Change in Disease Symptoms in Korean Participants With Moderate to Severe Active Rheumatoid Arthritis, Atopic Dermatitis, Ankylosing Spondylitis or Psoriatic ArthritisNCT04541810observationalPercentage of Participants With Adverse Events | — | Completed | — | Rheumatoid Arthritis (RA), Atopic Dermatitis (AD), Ankylosing Spondylitis (AS), Psoriatic Arthritis (PsA) | 2,369 | 2021-01-26 | 2025-12-31actual | — | 2026-02-12 |
| KYTX | Kyverna Therapeutics | $526M | A Long-Term Follow-Up Study for Participants Previously Treated With KYV-101NCT07403188observationalNumber of participants with treatment-related adverse events (AEs) as assessed by CTCAE v6.0 through Year 15 of long-term follow-up (LTFU). | — | Recruiting | Drug: KYV-101 | Refractory Lupus Nephritis, Myasthaenia Gravis, Stiff Person Syndrome, Rheumatoid Arthritis (RA), Multiple Sclerosis, Dermatomyositis, Systemic Sclerosis (SSc) | 70 | 2025-11-24 | Jan 2041 | ≤ 5,278 d | 2026-02-11 |
| PFE | Pfizer | $155.3B | Infliximab Biosimilar for Intravenous Drip Infusion 100 mg "Pfizer" Drug Use Investigation (Rheumatoid Arthritis)NCT03885037results2026-01-06observationalNumber of Participants With Adverse Drug Reactions (ADRs) | — | Completed | Drug: Infliximab [infliximab biosimilar 3] | Rheumatoid Arthritis | 77 | 2019-03-20 | 2024-11-29actual | — | 2026-01-06 |
| PFE | Pfizer | $155.3B | To Estimate the Efficacy of Treatment With TNFi as Monotherapy or Combination Therapy With MTX and Compare and Contrast Efficacy With Tofacitinib as Monotherapy and Combination Therapy in a Real World Setting.NCT05576051results2025-12-23observationalClinical Disease Activity Index (CDAI) Score at 6 Months for Tofacitinib Monotherapy vs Tofacitinib With Methotrexate (MTX) | — | Completed | Other: patterns of use of combination therapy and monotherapy | Rheumatoid Arthritis | 9,159 | 2015-06-04 | 2015-10-07actual | — | 2025-12-23 |
| ZBH | Zimmer Biomet | $18.9B | A Multicentre Observational Study to Evaluate Clinical Outcomes of the G7 Acetabular SystemNCT02036931results2025-12-19observationalHarris Hip Score | — | Completed | Device: Metal on Polyethylene articulation, Ceramic on Polyethylene articulation, Ceramic on Ceramic articulation | Noninflammatory Degenerative Joint Disease, Rheumatoid Arthritis | 162 | Mar 2013 | Dec 2024actual | — | 2025-12-19 |
| XBIT | XBiotech, Inc. | $69M | Natrunix in Combination With Methotrexate for Rheumatoid Arthritis TreatmentNCT06590090ACR 20 response | Phase 2 | Not yet recruiting | Biological: Natrunix 400 mg · Drug: Placebo, Methotrexate (MTX) | Rheumatoid Arthritis | 108 | 2026-07-15 | 2027-01-15 | in 148 d | 2025-12-09 |
| BMY | Bristol-Myers Squibb | $134.9B | A Post-marketing Study to Assess the Safety of Abatacept in Sweden Using the Swedish Rheumatology Quality Register (SRQ) RegisterNCT05413044observationalIncidence Rate of Overall Malignancies | — | Completed | — | Rheumatoid Arthritis, Psoriatic Arthritis | 140,706 | 2019-07-01 | 2025-08-22actual | — | 2025-12-08 |
| BMY | Bristol-Myers Squibb | $134.9B | A Post-marketing Study on the Safety of Abatacept Treatment in Denmark Using the Danish DatabaseNCT05421442observationalIncidence Rates of Overall Malignancies | — | Completed | — | Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA) | 38,396 | 2019-06-13 | 2025-08-22actual | — | 2025-12-08 |
| LLY | Eli Lilly and Company | $1.15T | A Study of Peresolimab (LY3462817) in Participants With Moderately-to-Severely Active Rheumatoid ArthritisNCT05516758results2025-12-04Percentage of Participants Achieving 20% Improvement in American College of Rheumatology Criteria (ACR20) Response at Week 12 | Phase 2 | Terminatedsponsor's stated reason: Study terminated due to an unfavourable benefit-risk profile observed in interim data analysis. | Drug: Peresolimab, Placebo | Rheumatoid Arthritis, Arthritis, Joint Diseases, Musculoskeletal Diseases, Rheumatic Diseases, Connective Tissue Diseases, Autoimmune Diseases, Immune System Diseases | 491 | 2022-08-31 | 2023-11-20actual | — | 2025-12-04 |
| PHIL.MI | Philogen S.p.A. | $1.1B | Safety and Preliminary Signs of Efficacy of F8IL10 for Intra-articular TreatmentNCT05622175MTD | Phase 1 | Withdrawnsponsor's stated reason: Study redesigned and registered under NCT07245992 (Protocol n° PH-F8IL10INTRA-03/24) | Drug: F8IL10 | Rheumatoid Arthritis | 0 | 2023-03-31 | 2025-12-31 | — | 2025-12-02 |
| AZN | AstraZeneca | — | A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics of Subcutaneous AZD6912 in Healthy ParticipantsNCT06115967Number of participants with adverse events (AEs) | Phase 1 | Completed | Drug: AZD6912, Placebo | Rheumatoid Arthritis | 40 | 2023-11-15 | 2025-10-16actual | — | 2025-12-01 |
| ZBH | Zimmer Biomet | $18.9B | Randomized Controlled Clinical Evaluation to Compare Vanguard Cruciate Retaining and AGC Total Condylar Knee ImplantsNCT01064063American Knee Society Knee Score | Not applicable | Completed | Device: Vanguard CR, AGC knee | Osteoarthritis, Rheumatoid Arthritis, Traumatic Arthritis | 150 | 2011-02-15 | 2013-12-15actual | — | 2025-11-26 |
| ZBH | Zimmer Biomet | $18.9B | A Prospective, Clinical Investigation of the Vanguard 360 Revision KneeNCT01542580observationalAMERICAN KNEE SOCIETY KNEE SCORE | — | Active, not recruiting | Device: Vanguard SSK 360 with PS Bearing, Vanguard SSK 360 with PSC bearing, Vanguard DA 360, Vanguard 360 TiNbN Femur with PS bearing, Vanguard 360 TiNbN Femur with PSC bearing | Osteoarthritis, Rheumatoid Arthritis, Traumatic Arthritis, Post Traumatic Deformity, Complications; Arthroplasty, Deformity of Limb | 255 | Mar 2012 | Dec 2031 | ≤ 1,959 d | 2025-11-25 |
| ZBH | Zimmer Biomet | $18.9B | BC Study of G7 Cup and Compatible Femoral StemsNCT03456622observationalSurvival of the implant system | — | Active, not recruiting | — | Non-inflammatory Degenerative Joint Disease, Osteoarthritis, Avascular Necrosis, Rheumatoid Arthritis | 230 | Nov 2015 | Jun 2029 | ≤ 1,045 d | 2025-11-25 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Adherence and Clinical Outcomes in Colombian Patients With an E-Device for Etanercept Administration in Rheumatoid ArthritisNCT05891600observationalAdherence (Pharmacy claims source) | — | Terminatedsponsor's stated reason: The study was terminated following a comprehensive review of the collected data and an assessment of the study's completeness. This decision was made to maintain scientific standards and ethical conduct, and to prevent potentially inaccurate results | Drug: Etaneracept Smartclic | Rheumatoid Arthritis | 60 | 2024-06-06 | 2025-05-30actual | — | 2025-11-20 |
| ABVX | Abivax S.A. | — | Study Evaluating the Long-Term Safety and Efficacy of ABX464 in Patients With Moderate to Severe Rheumatoid ArthritisNCT04049448Incidence of treatment-emergent adverse events in the ABX464 treated Patients, categorized by severity | Phase 2 | Completed | Drug: ABX464 | Rheumatoid Arthritis | 40 | 2019-10-25 | 2023-01-23actual | — | 2025-11-17 |
| ZBH | Zimmer Biomet | $18.9B | Comprehensive Reverse Shoulder Data CollectionNCT03404778observationalPain Score | — | Enrolling by invitation | Device: Biomet Comprehensive Reverse Shoulder | Arthropathy of Shoulder Region, Grossly Deficient Rotator Cuff, Osteoarthritis of the Shoulder, Rheumatoid Arthritis Without Humeral Metaphyseal Defects, Post-Traumatic Arthitis | 175 | 2010-03-07 | Dec 2026 | ≤ 133 d | 2025-10-30 |
| ZBH | Zimmer Biomet | $18.9B | G7 Freedom Constrained Vivacit-E LinersNCT05587244Survival of the study device | Not applicable | Enrolling by invitation | Device: Total Hip Arthroplasty with G7 Freedom Constrained Vivacit-E Liners | Osteoarthritis, Hip, Rheumatoid Arthritis, Non-Union Fracture, Trochanteric Fractures, Femoral Neck Fractures, Avascular Necrosis, Dislocation, Hip | 202 | 2023-05-08 | Dec 2037 | ≤ 4,151 d | 2025-10-20 |
| SNY | Sanofi | — | A Single Ascending Dose Study to Characterize the Pharmacokinetics, Safety, and Tolerability of SAR441566 in Healthy Adult Japanese Male Participants.NCT05858788Assessment of plasma pharmacokinetic (PK) parameters for SAR441566: Cmax | Phase 1 | Completed | Drug: SAR441566 | Rheumatoid Arthritis | 10 | 2023-05-15 | 2023-07-17actual | — | 2025-09-18 |
| SNY | Sanofi | — | A Randomized Placebo- and Active Comparator-controlled Study to Evaluate the Photosafety of SAR441566NCT05844735Treatment part I: Photosensitivity Index (PI) at 10 minutes post UV irradiation under Condition 1 | Phase 1 | Completed | Drug: SAR441566, Placebo, Ciprofloxacin | Rheumatoid Arthritis | 60 | 2023-05-22 | 2023-10-15actual | — | 2025-09-16 |
| ABBV | AbbVie | $457.5B | A Study of Oral Upadacitinib Tablets to Assess the Change in Disease Symptoms in Adult Canadian Participants With Moderate to Severe Rheumatoid ArthritisNCT04574492observationalPercentage of Participants Who Achieve Clinical Remission | — | Completed | — | Rheumatoid Arthritis (RA) | 413 | 2020-10-07 | 2024-07-30actual | — | 2025-09-03 |
| ABBV | AbbVie | $457.5B | A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to MethotrexateNCT02629159results2019-10-07Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12 | Phase 3 | Active, not recruiting | Drug: Placebo for Adalimumab, Adalimumab, Placebo for Upadacitinib, Upadacitinib | Rheumatoid Arthritis | 1,629 | 2015-12-01 | 2017-10-27actual | — | 2025-08-05 |
| PFE | Pfizer | $155.3B | A Study to Understand How Effective is Tofacitinib When Compared to Other Advanced Treatments in Patients With Rheumatoid ArthritisNCT06418529results2025-07-31observationalIncidence Rate of Low Disease Activity (LDA) or Remission Based on Clinical Disease Activity Index (CDAI) at 6-Months Follow-up: Tofacitinib vs. TNFi | — | Completed | Drug: tofacitinib, tumor necrosis factor inhibitors (TNFi), abatacept, tocilizumab or sarilumab | Rheumatoid Arthritis | 21,340 | 2024-05-15 | 2024-07-19actual | — | 2025-07-31 |
| KNSA | Kiniksa Pharmaceuticals, Ltd. | $6.3B | Study to Assess the Safety, Pharmacokinetics, and Efficacy of KPL-404 in Participants With Rheumatoid Arthritis With Inadequate Response or Intolerance to at Least One Biologic Disease-modifying Anti-rheumatic Drug or a Janus Kinase InhibitorNCT05198310results2025-07-22Cohorts 1 and 2: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) | Phase 2 | Completed | Drug: KPL-404, Placebo | Arthritis, Rheumatoid | 145 | 2021-12-14 | 2024-02-08actual | — | 2025-07-22 |
| SNY | Sanofi | — | A Study to Evaluate SAR441566 Efficacy and Safety in Adults With Rheumatoid ArthritisNCT06073093Proportion of participants achieving at least 20% improvement from baseline in the American College of Rheumatology (ACR) score at week 12 | Phase 2 | Completed | Drug: SAR441566, Placebo | Rheumatoid Arthritis | 264 | 2023-11-07 | 2025-06-18actual | — | 2025-07-11 |
| ZBH | Zimmer Biomet | $18.9B | G7 BiSpherical Acetabular Shell PMCF StudyNCT03266874observationalImplant survivorship is assessed counting the number of implant revisions | — | Active, not recruiting | — | Rheumatoid Arthritis, Osteoarthritis, Noninflammatory Degenerative Joint Disease, Avascular Necrosis, Correction of Functional Deformity, Non-Union Fracture, Femoral Neck Fractures, Trochanteric Fractures | 160 | 2017-12-10 | Dec 2029 | ≤ 1,229 d | 2025-06-25 |
| BMY | Bristol-Myers Squibb | $134.9B | Long-Term Outcomes With Abatacept In Biologic Treatment-Naive Rheumatoid Arthritis Patients In Japanese Clinical Practice SettingsNCT02758769observationalPercentage of achievement in simplified disease activity index (SDAI) remission after administration of abatacept | — | Completed | Biological: ORENCIA Subcutaneous Injection | Rheumatoid Arthritis | 303 | 2016-06-07 | 2023-11-15actual | — | 2025-06-22 |
| ZBH | Zimmer Biomet | $18.9B | Zimmer Continuum Metal on Polyethylene (MoP) PostMarket Clinical Followup (PMCF) StudyNCT01307384observationalSurvivorship | — | Active, not recruiting | Device: Continuum Metal on Polyethylene Acetabular System | Avascular Necrosis, Osteoarthritis, Inflammatory Arthritis, Post-traumatic Arthritis, Rheumatoid Arthritis | 165 | 2011-03-29 | Dec 2027 | ≤ 498 d | 2025-06-18 |
| ZBH | Zimmer Biomet | $18.9B | Exception Cementless Hip StemNCT04349046observationalImplant survival based on removal or intended removal of the device and determined using the Kaplan-Meier method | — | Active, not recruiting | Device: Total hip arthoplasty (THA) | Osteoarthritis, Hip, Rheumatoid Arthritis, Inflammatory Arthritis, Congenital Hip Dysplasia, Avascular Necrosis of Hip, Femoral Neck Fractures | 332 | 2021-01-01 | 2024-05-01actual | — | 2025-06-18 |
| ZBH | Zimmer Biomet | $18.9B | G7 Dual Mobility With Vivacit-E or Longevity PMCFNCT05548972Survival of the implant system | Not applicable | Enrolling by invitation | Device: G7 Dual Mobility with Vivacit-E bearing, G7 Dual Mobility Longevity bearing | Hip Osteoarthritis, Rheumatoid Arthritis, Joint Diseases, Avascular Necrosis, Dislocation, Hip, Femoral Neck Fractures, Trochanteric Fractures, Revision Surgeries | 358 | 2023-03-20 | Jan 2037 | ≤ 3,817 d | 2025-06-15 |
| PFE | Pfizer | $155.3B | Predictors of Response to Tofacitinib Treatment in Rheumatoid Arthritis PatientsNCT04079920results2025-06-08observationalPercentage of Participants With Remission and Low Disease Activity (LDA) at Month 6 Assessed Using 28-Joint Disease Activity Score C-Reactive Protein (DAS28-4 CRP) | — | Completed | — | Rheumatoid Arthritis | 198 | 2020-09-22 | 2023-02-08actual | — | 2025-06-08 |
| PFE | Pfizer | $155.3B | Study to Evaluate Safety and Effects of Tofacitinib and Biologic Disease Modifying Antirheumatic Drugs in People Treated for Rheumatoid ArthritisNCT05572567results2025-06-08observationalMean Incidence Rate of Total Cardiovascular Disease (CVD) Events | — | Completed | — | Arthritis, Rheumatoid | 1,972 | 2022-10-10 | 2022-10-10actual | — | 2025-06-08 |
| PFE | Pfizer | $155.3B | A Study to Learn About the Study Medicine Called Infliximab (Genetical Recombination)[Infliximab Biosimilar 3] in People With Rheumatoid Arthritis, Ulcerative Colitis, Crohn's Disease, or PsoriasisNCT05796245results2025-06-04observationalIncidence Rate of Serious Infections | — | Completed | — | Arthritis, Rheumatoid, Colitis, Ulcerative, Crohn Disease, Psoriasis | 2,207 | 2023-12-01 | 2024-03-14actual | — | 2025-06-04 |
| 4503.T | Astellas Pharma Inc | $26.0B | A Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects Who Have Had an Inadequate Response to MethotrexateNCT01554696Percentage of subjects achieving American College of Rheumatology Criteria 20 (ACR 20) response | Phase 2 | Completed | Drug: peficitinib, Placebo, methotrexate | Arthritis, Rheumatoid | 379 | 2012-07-06 | 2014-02-11actual | — | 2025-05-29 |
| ABBV | AbbVie | $457.5B | An Observational Study to Assess the Real-World Effectiveness of Upadacitinib in Adult Participants With Rheumatoid ArthritisNCT05170646observationalPercentage of Participants Achieving 28-Joint Disease Activity Score (DAS28) C-reactive protein (CRP) Clinical Remission | — | Completed | — | Rheumatoid Arthritis | 97 | 2022-03-14 | 2024-01-31actual | — | 2025-04-29 |
| ABBV | AbbVie | $457.5B | A Study of Oral Upadacitinib Tablets to Assess Treatment Patterns, Achievement of Treatment Targets and Maintenance of Response in Adult Participants With Moderate to Severe Rheumatoid ArthritisNCT04497597observationalPercentage of Participants Who Achieve Remission | — | Completed | — | Rheumatoid Arthritis (RA) | 1,532 | 2020-10-16 | 2024-05-15actual | — | 2025-04-13 |
| PFE | Pfizer | $155.3B | Changes of Depression After First-year of Tofacitinib in RA PatientsNCT03992781results2025-04-06observationalCUDOS Score: Baseline (Visit 1) and 12 Months (Visit 3) | — | Completed | — | Rheumatoid Arthritis | 73 | 2020-07-23 | 2024-02-07actual | — | 2025-04-06 |
| ZBH | Zimmer Biomet | $18.9B | Evaluate E1 Wear, Clinical Performance of E1 Liner in THA in Korean Patient PopulationNCT02087449observationalHHS score | — | Terminatedsponsor's stated reason: Sponsor decided to terminate study. | Device: E1-Hip Bearing | Osteoarthritis, Avascular Necrosis, Traumatic Arthritis, Rheumatoid Arthritis, Legg-perthes Disease | 100 | Feb 2013 | Dec 2017actual | — | 2025-04-02 |
| BMY | Bristol-Myers Squibb | $134.9B | Safety Study of Abatacept to Treat Rheumatoid ArthritisNCT01247766observationalSerious infection | — | Completed | — | Rheumatoid Arthritis | 6,367 | 2010-12-31 | 2014-12-31actual | — | 2025-03-21 |
| ABBV | AbbVie | $457.5B | An Observational Study to Assess the Impact of Upadacitinib in Adult Hungarian Participants With Moderate to Severe Rheumatoid Arthritis (RA) in Real-World PracticeNCT05327920observationalPercentage of Participants Achieving 28-Joint Disease Activity Score (DAS28) C-reactive protein (CRP) Remission following initiation of treatment with Upadacitinib | — | Completed | — | Rheumatoid Arthritis | 93 | 2022-04-20 | 2024-04-22actual | — | 2025-03-14 |
| AMGN | Amgen | $229.9B | Study to Evaluate Safety and Efficacy of CCX 354-C in Subjects With Rheumatoid ArthritisNCT01027728Subject Incidence of Adverse Events | Phase 1/2 | Completed | Drug: CCX 354-C | Rheumatoid Arthritis | 24 | Dec 2009 | Jul 2010actual | — | 2025-03-06 |
| AMGN | Amgen | $229.9B | A Study to Evaluate the Safety and Efficacy of CCX354-C in Subjects With Rheumatoid Arthritis Partially Responsive to Methotrexate TherapyNCT01242917Subject incidence of adverse events | Phase 2 | Completed | Drug: CCX-354-C, Placebo, CCX354-C | Rheumatoid Arthritis | 159 | Sep 2010 | Jul 2011actual | — | 2025-03-06 |
| BMY | Bristol-Myers Squibb | $134.9B | A Study to Compare the Response to Treatment With Abatacept vs Adalimumab, on Background Methotrexate, in Adults With Early, Seropositive, and Shared Epitope-positive Rheumatoid Arthritis and an Inadequate Response to MethotrexateNCT04909801results2024-10-15Percentage of SE+ Participants Meeting 50% Improvement in American College of Rheumatology Criteria (ACR50) Response at Week 24 | Phase 3 | Active, not recruiting | Drug: Abatacept, Adalimumab, Methotrexate | Rheumatoid Arthritis | 338 | 2021-09-15 | 2023-06-14actual | — | 2025-02-19 |
| ZBH | Zimmer Biomet | $18.9B | Arcos Revision Stem: Evaluation of Clinical PerformanceNCT01820611results2025-01-20observationalSurvivorship | — | Completed | Device: Arcos Revision Stem System | Osteoarthritis, Avascular Necrosis, Rheumatoid Arthritis, Deformity, Fracture, Complications; Arthroplasty | 74 | Feb 2013 | 2021-06-14actual | — | 2025-01-20 |
| XBIT | XBiotech, Inc. | $69M | Natrunix or Placebo in Combination With Methotrexate in Rheumatoid ArthritisNCT05363891ACR 20 response rate at 12 weeks. | Phase 2 | Completed | Drug: Natrunix, Placebo | Rheumatoid Arthritis | 243 | 2023-08-08 | 2024-10-31actual | — | 2025-01-16 |
| ZBH | Zimmer Biomet | $18.9B | NexGen TM Tibia Clinical Outcomes StudyNCT03272373results2024-12-05Radiograph Assessment of Progressive Tibial Radiolucencies | Not applicable | Completed | Device: NexGen TM Monoblock Tibia, NexGen TM Modular Tibia | Osteoarthritis, Rheumatoid Arthritis, Traumatic Arthritis, Polyarthritis, Collagen Disorders and/or Avascular Necrosis of the Femoral Condyle, Post-traumatic Loss of Joint Configuration, Moderate Valgus, Varus, or Flexion Deformities | 160 | 2017-10-03 | 2023-03-30actual | — | 2024-12-30 |
| ZBH | Zimmer Biomet | $18.9B | PMCF Study on the Safety, Performance and Clinical Benefits Data of the NexGen TM Augmentation PatellaNCT05253976observationalThe incidence and frequency of revisions, complications and adverse events. | — | Withdrawnsponsor's stated reason: Study had to be terminated before first patient got enrolled due to insufficient case number. | — | Rheumatoid Arthritis, Non-inflammatory Degenerative Joint Disease, Functional Deformity, Revision Total Knee Arthroplasty | 0 | Sep 2022 | 2034-12-31 | in 3,055 d | 2024-12-24 |
| AMGN | Amgen | $229.9B | Study to Assess the Safety and Efficacy of Modified-Release Prednisone (Lodotra®) Therapy in Patients With Active Rheumatoid ArthritisNCT00650078results2012-12-13ACR 20 Response Rate at Visit 4 | Phase 3 | Completed | Drug: MR prednisone, Placebo | Rheumatoid Arthritis | 350 | Mar 2008 | May 2009actual | — | 2024-12-18 |
| AMGN | Amgen | $229.9B | Safety Study of HZT-501 in Patients Who Require Long-Term Daily Non-steroidal Anti-inflammatory Drug TreatmentNCT00984815results2013-07-25Number of Participants With Treatment Emergent Adverse Events | Phase 3 | Completed | Drug: HZT-501 | Osteoarthritis, Rheumatoid Arthritis, Chronic Low Back Pain, Chronic Regional Pain Syndrome, Chronic Soft Tissue Pain | 86 | Sep 2009 | Jul 2011actual | — | 2024-12-18 |
| AMGN | Amgen | $229.9B | A Non-Interventional Study of RAYOS in Adult Patients With Rheumatoid ArthritisNCT02287610results2017-02-03observationalMean Change in Severity of Morning Stiffness (Using 100mm VAS) From Baseline (Week 0) to Final Follow-Up Visit | — | Completed | Drug: RAYOS (delayed-release prednisone) | Rheumatoid Arthritis | 75 | Nov 2014 | Oct 2015actual | — | 2024-12-18 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
How Rheumatoid Arthritis is matched — 8 exact registry spellings
A study is on this page when its ClinicalTrials.gov record names one of these conditions exactly (letter case aside). Nothing is matched by substring or stem, so a longer condition that merely contains one of these words is a different page. The list was curated by hand and last measured 2026-08-19; a spelling filed by only one study was not curated, so the counts here are a floor rather than the registry's own total for the disease.
- Rheumatoid Arthritis
- Arthritis, Rheumatoid
- Rheumatoid Arthritis (RA)
- Active Rheumatoid Arthritis
- Moderate to Severe Rheumatoid Arthritis
- Rheumatoid Arthritis (RA
- Rheumatoid Arthritis Without Humeral Metaphyseal Defects
- Rheumatoid Arthritis of Hip
Permalink · All conditions · Catalyst calendar · Every registered study · Search the whole pipeline for “Rheumatoid Arthritis” (a text search, wider than this page)